The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology Therapeutics
Hosted By : Andrea CharlesNovember 6, 2012
Rate this Podcast:
(Be the First!)
About this Podcast...
In this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about what trends he is witnessing in the improvement of safety assessments, his top 3 preclinical considerations in the discovery and development of novel oncology therapeutics and the implications and future considerations for use of computational biology in clinical drug development.
|
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
Rate this Podcast:
(Be the First!)
Events of Interest
-
Exploring Challenges and Opportunities in Predictive Safety Tools: Trends from Industry-Wide Surveys
January 13, 2012
Register Now -
Taking EDC to the next level: Moving from point solutions to an eClinical ecosystem
April 4, 2013
Register Now -
EU Product Launch – Key Considerations for Successful Niche and Orphan Drug Product Launches
February 9, 2012
Register Now -
hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing
March 28, 2012
Register Now





Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!